Nextcure to present phase 1b data of nc410 in combination with pembrolizumab at asco 2024

Beltsville, md., april 24, 2024 (globe newswire) --  nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator eric s.
NXTC Ratings Summary
NXTC Quant Ranking